McQuilling and IFCHOR form Latin American JV

first_imgManu Ravano, CEO of IFCHOR, said, “We firmly believe that a combination of IFCHOR’s dry bulk expertise, competitiveness and connections and McQuilling’s Latin American history and presence will deliver clients with a highly effective shipbroking solution. The Latin American market, especially in terms of cargo, continues to grow and this partnership with McQuilling will enable us to provide our clients with greater access to the region.” Sea News, September 27 US headquartered McQuilling has a significant Latin American footprint and opened its Lima office in 2007 to serve as the base for its Latin American business. Switzerland headquartered IFCHOR has extensive expertise in dry bulk with a strong presence in the Capesize, Panamax and Handy to Ultramax international markets. John Schmidt, CEO of McQuilling, said, “McQ-IFCHOR SA is a bold and exciting move by both companies. Our joint venture with IFCHOR is consistent with McQuilling’s long term expansion program of joining with a valued partner in a strategic market.” Leading independent shipbrokers McQuilling Partners, Inc. and IFCHOR are pleased to announce the formation of McQ-IFCHOR SA, a joint venture focused on the Latin American dry bulk chartering and advisory services. McQ-IFCHOR SA will be led by Jean Magot from McQuilling’s Lima, Peru office. While the venture is in the process of hiring experienced personnel, further experienced staff has been assigned to the venture from McQuilling and IFCHOR Seattle, New York and Lausanne offices. Author: Baibhav Mishralast_img read more

Get ready for the 2019 Kawasaki Ninja ZX-6R

first_imgDocuments were filed to the California Air Resources Board (CARB) regarding the emissions output of the 2019 supersport machine. The new ZX-6R is heading towards the Euro5 emissions regulations and it is said to produce only half of the emissions compared to the previous model. As of now, no other details is being shared about this upcoming supersport machine but one thing is for sure; middleweight sports bikes are going into a whole new era and Kawasaki is one of the manufacturers ready to face the challenge head-on. Stay tuned to Bikes Republic for more updates.WorldSBK: Tom Sykes is leaving Kawasaki–Ads– It looks like Kawasaki is currently working on a brand new 2019 Kawasaki Ninja ZX-6R. Rumours on a brand new Kawasaki supersport machine is currently heating up as talks of the 2019 Kawasaki Ninja ZX-6R is currently underway. Based on a few key sources, it’s not just talk but Kawasaki is walking the walk with this one.First and foremost, a document filed by Kawasaki Heavy Industries (KHI) to the California Air Resources Board (CARB) is probably the biggest indicator of the next-generation middleweight Ninja. Retaining its 636cc inline-four engine configuration, it is stated that it has the ability to produce half of the emissions when compared to the previous ZX-6R.Works from Team Green to make their sports bike more ‘green’ are all part of their effort to conform to the Euro4 emissions regulations. Due to this, rumours are also going around that the current power output of the ZX-6R at around 129hp might see a slight decrease for the 2019 model.This also suggests that it won’t just be an updated version but rather, a brand-new Ninja ZX-6R built from the ground up. Other possible details of the 2019 machine include:New three-way closed-loop catalystOverall weight decrease (estimated around 195kg)Reworked dimensions for improved agility (wider & shorter)More aerodynamic bodywork (aerofairings?)Updated electronics (possibly an addition of Inertial Measurement Unit or IMU)last_img read more

New pill for breast cancer diagnosis could do a better job than

first_imgApr 30 2018As many as one in three women treated for breast cancer undergo unnecessary procedures, but a new method for diagnosing it could do a better job distinguishing between benign and aggressive tumors.Researchers at the University of Michigan are developing a pill that makes tumors light up when exposed to infrared light, and they have demonstrated that the concept works in mice.Mammography is an imprecise tool. About a third of breast cancer patients treated with surgery or chemotherapy have tumors that are benign or so slow-growing that they would never have become life-threatening, according to a study out of Denmark last year. In other women, dense breast tissue hides the presence of lumps and results in deaths from treatable cancers. All that, and mammograms are notoriously uncomfortable.Related StoriesCancer killing capability of lesser-known immune cells identifiedEmbrace your natural skin tone to prevent skin cancer, say expertsHow cell-free DNA can be targeted to prevent spread of tumors”We overspend $4 billion per year on the diagnosis and treatment of cancers that women would never die from,” said Greg Thurber, U-M assistant professor of chemical engineering and biomedical engineering, who led the team. “If we go to molecular imaging, we can see which tumors need to be treated.”The move could also catch cancers that would have gone undetected. Thurber’s team uses a dye that responds to infrared light to tag a molecule commonly found on tumor cells, in the blood vessels that feed tumors and in inflamed tissue. By providing specific information on the types of molecules on the surface of the tumor cells, physicians can better distinguish malignant cancer from a benign tumor.Compared to visible light, infrared light penetrates the body easily–it can get to all depths of the breast without an X-ray’s tiny risk of disrupting DNA and seeding a new tumor. Using a dye delivered orally rather than directly into a vein also improves the safety of screening, as a few patients in 10,000 can have severe reactions to intravenous dyes. These small risks turn out to be significant when tens of millions of women are screened every year in the U.S. alone.But it’s not easy to design a pill that can carry the dye to the tumor.”To get a molecule absorbed into the bloodstream, it needs to be small and greasy. But an imaging agent needs to be larger and water-soluble. So you need exact opposite properties,” Thurber said.Fortunately, they weren’t the only people looking for a molecule that could get from the digestive system to a tumor. The pharmaceutical company Merck was working on a new treatment for cancer and related diseases. They got as far as phase II clinical trials demonstrating its safety, but unfortunately, it wasn’t effective.”It’s actually based on a failed drug,” Thurber said. “It binds to the target, but it doesn’t do anything, which makes it perfect for imaging.”The targeting molecule has already been shown to make it through the stomach unscathed, and the liver also gives it a pass, so it can travel through the bloodstream. The team attached a molecule that fluoresces when it is struck with infrared light to this drug. Then, they gave the drug to mice that had breast cancer, and they saw the tumors light up. Source: read more